TrialClinical cancer research : an official journal of the American Association for Cancer Research2021

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.

Adriana Estrada-Bernal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.